Overview
Verruciform xanthoma (VX) is a rare, benign proliferative lesion primarily affecting the oral mucous membranes, although it can also occur in extraoral locations such as the skin and genital mucosa. Characterized by the accumulation of foamy histiocytes within the connective tissue papillae, VX presents a unique histopathological profile that distinguishes it from other verrucous lesions. The lesion typically manifests as a white, verrucous, or papillary growth, often found on the palate, buccal mucosa, gingiva, and tongue. Despite its benign nature, VX can pose diagnostic challenges due to its varied clinical presentations and the need for histopathological confirmation. Understanding the pathophysiology, epidemiology, clinical features, and management strategies is crucial for effective patient care and follow-up.
Pathophysiology
The pathophysiology of verruciform xanthoma (VX) revolves around a chronic inflammatory response characterized by the accumulation of foamy histiocytes within the connective tissue papillae of the oral mucosa. Immunohistochemical analyses have revealed that these foam cells predominantly consist of reparative (RM3/1) and resident (25F9) macrophages, with fewer inflammatory (27E10) macrophages, indicating a predominantly reparative rather than inflammatory process [PMID:17335374]. Histomorphologically, the hallmark of VX is the replacement of connective tissue between epithelial ridges by these foam cells, which are derived from the monocyte/macrophage lineage [PMID:12676251]. Ultrastructural studies suggest that the lipid accumulation in these histiocytes originates from degenerating keratinocytes, highlighting a potential mechanism where epithelial cell degeneration triggers the formation of foam cells [PMID:10640929]. Initiation of VX lesions often begins within the epithelium, involving entrapment of epithelial cells followed by lipid degeneration and subsequent foam cell accumulation [PMID:1057149]. This process underscores the intricate interplay between epithelial and connective tissue components, leading to the characteristic verruciform appearance of the lesion.
Epidemiology
Verruciform xanthoma (VX) predominantly affects adults, with a median age of 55 years (range 13-86 years) and a slight male predominance (male-to-female ratio of 1.2:1) [PMID:37420145]. The most frequently affected oral sites include the palate (22%), buccal mucosa (16%), gingiva (15%), and tongue (12%). However, the condition is not confined to oral mucosa; it can also present in extraoral locations, though less commonly. Studies comparing non-Japanese and Japanese populations reveal minimal significant ethnic differences, with the gingival margin being a common site across both groups [PMID:12676251]. Despite its rarity, VX has been reported in diverse demographics, including the first documented cases in the United Kingdom and a black patient, expanding the known clinical spectrum [PMID:6934808, PMID:276795]. These reports emphasize the importance of recognizing VX beyond typical demographic profiles and highlight the need for broader clinical awareness to ensure timely diagnosis and management.
Clinical Presentation
Verruciform xanthoma (VX) typically presents as a white, verrucous, or papillary lesion with a rough surface, often resembling other benign oral growths. Lesions can appear as sessile or pedunculated growths, characterized by their verruciform or flat epithelial patterns, covered by vacuolated foam cells [PMID:12676251]. Clinical observations indicate that extraoral lesions tend to be larger and exhibit more prominent wedge-shaped parakeratosis and keratin projections above the epithelium, distinguishing them from oral lesions [PMID:37420145]. A typical presentation involves a white lesion in the gingiva that resists removal by scraping and evolves into a rough surface, characteristic of VX [PMID:30224613]. Disseminated cases, involving multiple sites such as oral, cutaneous, and genital areas, highlight the multifocal nature of the condition [PMID:24999643]. An atypical presentation might manifest as a well-circumscribed, asymptomatic nodule, contrasting with the usual rough, warty surface and larger size, underscoring the variability in clinical appearance [PMID:3466940]. Detailed clinical descriptions often include features like a shaggy, parakeratin-covered surface and elongated rete pegs, aiding in early recognition [PMID:276795].
Diagnosis
Diagnosing verruciform xanthoma (VX) relies heavily on histopathological examination, which is essential for identifying the hallmark presence of vacuolated, foamy histiocytes within the connective tissue papillae [PMID:12676251]. Microscopic features such as wedge-shaped parakeratosis and keratin projections are more prevalent in extraoral lesions, aiding in accurate diagnosis across different sites [PMID:37420145]. Initial cytological assessments, such as exfoliative cytology, may classify lesions as benign but often fall short of providing a definitive diagnosis, necessitating histopathological confirmation [PMID:30224613]. Immunohistochemical studies using antibodies like RM3/1, 25F9, and 27E10 help characterize the macrophage phenotypes consistently present in VX lesions, regardless of the oral mucosal site [PMID:17335374]. Ultrastructural analyses and electron microscopy further support diagnosis by revealing the ultrastructural details of foam cell formation and lipid accumulation [PMID:1057149]. Blood parameters, including lipid profiles, typically remain normal, helping rule out systemic lipid disorders in differential diagnosis [PMID:1057149]. Clinicians must recognize that clinical characteristics alone are insufficient for definitive diagnosis, emphasizing the critical role of microscopic examination in confirming VX.
Differential Diagnosis
Differentiating verruciform xanthoma (VX) from other verrucous growths and mucosal lesions can be challenging due to overlapping clinical features. Lesion size, histopathological characteristics, and specific morphological traits are crucial in distinguishing VX from conditions like verruca vulgaris, condyloma acuminatum, and other benign tumors [PMID:37420145]. Preoperative differentiation often proves difficult, frequently leading to misdiagnosis as papilloma or similar benign tumors [PMID:30224613]. Clinicians must consider a broad differential that includes other histiocytic proliferations and chronic inflammatory conditions. Blood parameters, such as normal levels of triglycerides, cholesterol, and glucose, can help exclude systemic lipid disorders, narrowing down the differential diagnosis [PMID:1057149]. Careful histopathological examination remains pivotal in ruling out these alternatives by identifying the unique foam cell accumulation and characteristic ultrastructural features specific to VX.
Management
The management of verruciform xanthoma (VX) often involves surgical excision due to the benign yet persistent nature of the lesions. Many cases are treated empirically as benign tumors, with definitive diagnosis occurring postoperatively [PMID:30224613]. Various surgical techniques, including excision, shave excision, and electrosection, have been employed, with surgical removal generally yielding satisfactory cosmetic outcomes [PMID:24999643]. Despite attempts with medical treatments such as salicylic acid, topical corticosteroids, antibiotics, and chlorhexidine, these interventions have shown limited efficacy in resolving VX lesions, though they may provide symptomatic relief [PMID:24999643]. Advanced modalities like pulsed dye laser and x-ray therapy have also been explored but have proven ineffective in managing large cutaneous VX lesions [PMID:10640929]. Postoperative follow-up is crucial, as evidenced by cases showing no recurrence at 1-year follow-up post-excision, indicating a favorable long-term prognosis [PMID:30224613]. Given the ineffectiveness of non-surgical treatments, the focus often shifts to achieving cosmetic improvement through meticulous surgical techniques and regular follow-up to monitor for recurrence.
Prognosis & Follow-up
The prognosis for verruciform xanthoma (VX) following surgical excision is generally favorable, with most patients experiencing no recurrence at long-term follow-up intervals, such as 1 year post-surgery [PMID:30224613]. However, the literature emphasizes the importance of recognizing clinical and morphological variations to tailor effective management strategies and ensure adequate follow-up [PMID:37420145]. Given the limited response to medical treatments, the emphasis in follow-up care is on monitoring for recurrence and addressing cosmetic concerns. Regular clinical assessments and histopathological confirmation when necessary are recommended to manage any potential recurrence or atypical presentations effectively. While explicit long-term prognosis data are limited, the absence of systemic involvement and the benign nature of VX suggest a positive outlook with appropriate surgical intervention and vigilant follow-up.
Key Recommendations
References
1 Javadi T, Saeed F, Parker DC, Magliocca KR. Verruciform Xanthoma: Clinical and Morphologic Spectrum Across Oral, Genital, and Cutaneous Sites. Head and neck pathology 2023. link 2 Onda T, Hayashi K, Shiraishi N, Takano N, Shibahara T. Verruciform Xanthoma with Equivocal Exfoliative Cytological Diagnosis. The Bulletin of Tokyo Dental College 2018. link 3 Tang R, Kopp SA, Cobb C, Halpern AV. Disseminated verruciform xanthoma: a case report. Cutis 2014. link 4 Qi Y, Sun Q, Yang P, Song A. A case of multiple verruciform xanthoma in gingiva. The British journal of oral & maxillofacial surgery 2014. link 5 Rawal SY, Kalmar JR, Tatakis DN. Verruciform xanthoma: immunohistochemical characterization of xanthoma cell phenotypes. Journal of periodontology 2007. link 6 Philipsen HP, Reichart PA, Takata T, Ogawa I. Verruciform xanthoma--biological profile of 282 oral lesions based on a literature survey with nine new cases from Japan. Oral oncology 2003. link00088-x) 7 Connolly SB, Lewis EJ, Lindholm JS, Zelickson BD, Zachary CB, Tope WD. Management of cutaneous verruciform xanthoma. Journal of the American Academy of Dermatology 2000. link90108-7) 8 Correll RW, DeBoom GW. A well-circumscribed, asymptomatic, sessile nodule on the right side of the soft palate. Journal of the American Dental Association (1939) 1986. link 9 Hume WJ, Smith CJ, Franklin CD. Verruciform xanthoma. The British journal of oral surgery 1980. link90034-7) 10 Graff SG, Burk JL, McKean TW. Verruciform xanthoma. First case reported in a black person. Oral surgery, oral medicine, and oral pathology 1978. link90152-4) 11 Zegarelli DJ, Zegarelli-Schmidt EC, Zegarelli EV. Verruciform xanthoma. Further light and electron microscopic studies, with the addition of a third case. Oral surgery, oral medicine, and oral pathology 1975. link90156-5)